None listed
Conditions
Brief summary
This study aims to find out how well using immunotherapy on its own before starting standard chemotherapy, or starting treatment with immunotherapy at the same time as standard chemotherapy, helps to reduce tumour size before surgery in patients with previously untreated early stage triple negative breast cancer. Who is it for? You may be eligible for this study if you are 18 years or older and have been diagnosed with triple negative breast cancer that is potentially operable and has not spread to other parts of your body. Tumour block/sections from the initial diagnostic core biopsy must be available. Trial Details: Arms A & B (completed recruitment in April 2022) Participants will be randomised 1:1 to either: Arm A: Nivolumab only for 2 weeks, followed by Nivolumab + Carboplatin + Paclitaxel for a further 12 weeks, followed by surgery. Paclitaxel is given weekly; Nivolumab and Carboplatin are given every 3 weeks for 4 cycles. Arm B: Nivolumab + Carboplatin + Paclitaxel for 12 weeks. Paclitaxel is given weekly; Nivolumab and Carboplatin are given every 3 weeks for 4 cycles. After 12 weeks, there will be a further 2 weeks of treatment with Nivolumab only, followed by surgery. All treatments are administered intravenously. The following biological samples will be collected: * Tumour biopsy at diagnosis, after Nivolumab monotherapy lead-in (Arm A) or before Cycle 2 (Arm B), and from the surgical specimen should invasive residual disease remain. * Blood samples at Baseline (before the first dose of study treatment), after Cycle 1 (Arm A) or after Cycle 2 (Arm B) and at the End of Treatment Visit. Arm C: Nivolumab + Relatlimab only for 2 weeks, followed by Nivolumab + Relatlimab (together) + Carboplatin + Paclitaxel for a further 12 weeks, followed by surgery. Paclitaxel and carboplatin are given weekly; Nivolumab + Relatlimab are given every 3 weeks for 4 cycles. You are recommended to continue Nivolumab after surgery every 4 weeks for 9 cycles where pembrolizumab is not available. All treatments are given intravenously. The following biological samples will be collected: * Tumour biopsy at diagnosis, after 2 week lead-in, and from the surgical specimen should invasive residual disease remain. * Blood samples at Baseline (before the first dose of study treatment), after Cycle 1, before surgery, 2-4 weeks after surgery, at the End of Treatment Visit, and 6 months, 12 months after registration and at each Survival Follow up Visit.. All participants (Arms A, B & C) will be regularly monitored throughout treatment to evaluate their health. There will be an end of treatment visit 30 days after surgery. Follow-up visits will occur every 6 months after surgery for up to 3 years post-randomisation. Further treatment will be at the discretion of the participant and their treating clinician. It is hoped this research will provide new treatment options for people with triple negative breast cancer.
Interventions
ARM A - Nivolumab window
Nivolumab monotherapy 240 mg IV, 2 weeks later followed by Nivolumab 360 mg IV with Carboplatin AUC5 once every 3 weeks for 4 cycles and Paclitaxel 80 mg/m^2 every week for 12 weeks as an IV infusion administered per institutional guidelines. Nivolumab should be administered 30 minutes before administration of chemotherapy. This will be followed by surgery a minimum of 2 weeks and a maximum of 4 weeks after the last dose of paclitaxel.
ARM B - Concurrent Nivolumab
Nivol
ARM A - Nivolumab window Nivolumab monotherapy 240 mg IV, 2 weeks later followed by Nivolumab 360 mg IV with Carboplatin AUC5 once every 3 weeks for 4 cycles and Paclitaxel 80 mg/m^2 every week for 12 weeks as an IV infusion administered per institutional guidelines. Nivolumab should be administered 30 minutes before administration of chemotherapy. This will be followed by surgery a minimum of 2 weeks and a maximum of 4 weeks after the last dose of paclitaxel. ARM B - Concurrent Nivolumab Nivolumab 360 mg IV with Carboplatin AUC5 once every 3 weeks for 4 cycles and Paclitaxel 80 mg/m^2 every week for 12 weeks. Nivolumab should be administered 30 minutes before administration with chemotherapy. 12 weeks of concurrent treatment will immediately followed by Nivolumab monotherapy 240 mg IV. Surgery will follow treatment a minimum of 2 weeks and a maximum of 4 weeks later after the last dose of paclitaxel. ARM A & B: First participant recruited 6 July 2020; final participant recruited 1 April 2022. 110 participants were recruited to ARMS A & B. ARM C - Nivolumab + Relatlimab Fixed Dose Combination Nivolumab 240 mg IV Day 1 + relatlimab 240mg (fixed dose combination) IV Day 1; 2 weeks later followed by nivolumab 360 mg IV Day 1 every 3 weeks for 4 cycles + relatlimab 360mg (fixed dose combination) IV Day 1 every 3 weeks for 4 cycles with carboplatin area under the curve 1.5 IV x 12 weeks and paclitaxel 80 mg/m^2 IV weekly x 12 weeks. Granulocyte-Colony Stimulating Factor (G-CSF) prophylaxis may be given on after Day 1 of each cycle of carboplatin/paclitaxel, or as needed. Surgery will follow treatment a minimum of 2 weeks and a maximum of 4 weeks later after the last dose of paclitaxel. Participants will be recommended to continue adjuvant nivolumab at a dose of 480 mg IV every 4 weeks for 9 cycles where access to pembrolizumab is not available. Study treatment is administered at clinic/study visits.
Sponsors
Breast Cancer Trials
Study design
Allocation
Randomised controlled trial
Intervention model
Other
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1) Female or male, age >= 18 years. 2) Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. 3) Previously untreated non-metastatic (M0) TNBC meeting Stage I or II criteria according to AJCC Cancer Staging Manual, 8th Edition, 2017 as assessed by the local investigator on the basis of mammogram (MMG) and/or ultrasound (US) of the breasts, and US or clinical examination of the axilla. a) Stage I cT1c cN0; Stage IIA cT1 cN1; cT2 cN0; Stage IIB cT2 cN1; cT3 cN0. b) Contralateral in situ only disease is permitted; c) In the event of abnormal imaging of the axilla, nodal status should be confirmed by cytology. 4) Clinically node positive participants should undergo computed tomography (CT) scan or PET CT of chest/abdomen (and bone scan if clinically indicated) to exclude metastases. Those participants with equivocal finding on staging should have biopsies performed to confirm or exclude metastatic disease if possible. 5) Non-metastatic, potentially operably, unilateral triple negative breast cancer, histologically defined as: a) ER negative: with < 1% of tumour cells positive for ER by IHC irrespective of staining intensity; AND b) PR negative: with < 10% tumour cells positive for PR by IHC irrespective of staining intensity; AND c) HER2 negative: i) IHC 0, as defined by no staining observed or membrane staining that is incomplete and is faint/barely perceptible and within <= 10% of the invasive tumour cells; OR ii) IHC 1+, as defined by incomplete membrane staining that is faint/barely perceptible and within > 10% of invasive tumour cells; OR iii) ISH (FISH or SISH) negative based on: * Single-probe average HER2 copy number < 4.0 signals/cell; OR * Dual-probe HER2/CEP17 ratio < 2.0 with an average HER2 copy number < 4.0 signals/cell; OR * As per ASCO-CAP 2018 Guidelines. 6) Able to commence study treatment within 14 days of randomisation/registration. 7) Surgery is able to be undertaken within 4 weeks of final dose of neoadjuvant IV therapy. Pre-operative radiation is not permitted for any participant with operable cancer after final paclitaxel. 8) Adequate organ function. All screening laboratory tests should be performed within 14 days of randomisation/registration. 9) Screening laboratory values must meet the following criteria (using NCI-CTCAE V5.0): a) WBC >= 2 x 10^9/L; b) Neutrophils >= 1.5 x 10^9/L; c) Platelets >= 100 x 10^3/µL; d) Haemoglobin >= 9.0 g/dL; e) Serum creatinine <= 1.5 x ULN or calculated creatinine clearance >= 50 mL/min (using the Cockcroft Gault formula); f) AST/ALT <= 3.0 x ULN; g) Total bilirubin <= 1.5 x ULN except participants with Gilbert Syndrome who must have a total bilirubin level <= 3.0 x ULN. 10) Left ventricular ejection fraction (LVEF) of >= 50% assessed by echocardiogram (ECHO) or multigated acquisition (MUGA) scan performed at screening (no more than 4 weeks before study entry). 11) Negative pregnancy test or confirmation of post-menopausal status for female participants. Women who have undergone surgical sterilisation (bilateral oophorectomy, bilateral salpingectomy/tubal ligation, or hysterectomy) do not require pregnancy testing. a) Negative urine or serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG within 14 days of randomisation/registration and within 7 days before the first dose of study treatment. The pregnancy test will be repeated within 24 hours before the first dose if outside this window. OR: b) Women will be considered post-menopausal if they have been amenorrhoeic for 12 months without an alternative medical cause. The following age-specific requirements apply: i) Women < 50 years of age would be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments with no Mirena® IUD in situ and if they have luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the post-menopausal range for the institution. ii) Women >= 50 years of age would be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatments with no Mirena IUD in situ or endometrial ablation. If Mirena IUD or endometrial ablation and age < 60 years, LH and FSH should be in the postmenopausal range. 12) Female participants of childbearing potential must agree to follow instruction for method(s) of contraception from the time of enrolment for the duration of treatment and for at least 5 months after completing Nivolumab and/or Relatlimab treatment; 13) Be willing and able to provide written informed consent for the study. The participant may also provide consent for future unspecified biomedical research. However, the participant may participate in the main study without participating in future unspecified biomedical research. 14) The participant has been informed of and agrees to data transfer and handling, in accordance with national data protection guidelines. 15) The participant agrees to make tumour (diagnostic core biopsy and surgical specimen) available for submission for central pathology review and to conduct translational studies as part of this protocol.
Exclusion criteria
1) Confirmed presence of AJCC 8th edition anatomic Stage 3 or 4 disease. 2) Tumour of any size considered inoperable at presentation. 3) Multifocal* or bilateral invasive breast cancer. * Refer to AJCC 8th Edition: use clinical judgement if satellite nodes are close as to whether this represents truly multifocal disease. 4) Has received prior chemotherapy, targeted therapy, radiation therapy, immunotherapy that target immune checkpoints, co-stimulatory or co-inhibitory pathways for T-cell receptors within the past 12 months. 5) Will be offered neoadjuvant breast radiation therapy. 6) Undergone or planned for sentinel lymph node biopsy before study therapy. 7) Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks before randomisation/registration. Note: participant will be excluded if he/she received an investigational agent with anticancer or anti-proliferative intent within the last 12 months. 8) Any concurrent anti-neoplastic therapy (i.e. chemotherapy, hormonal therapy, immunotherapy, extensive, non-palliative radiation therapy, or standard or investigational agents for treatment of breast cancer) not already specified in the protocol. 9) Prior malignancy active within the previous 3 years before randomisation/registration, except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast. 10) Other active non-breast malignancy requiring concurrent intervention. 11) Has significant cardiovascular disease such as myocardial infarction, acute coronary syndrome or coronary angioplasty/stenting/bypass grafting within the last 6 months, congestive cardiac failure (CHF) New York Heart Association (NYHA) classification IV or history of CHF NYHA III or IV. 12) Participants with an active, known or suspected autoimmune disease are not eligible. Participants with the following are eligible to participate: a) Type I diabetes mellitus; b) Hypothyroidism only requiring hormone replacement; c) Skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment; or d) Conditions not expected to recur in the absence of an external trigger. 13) Participants with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomisation/registration are not eligible. Inhaled or topical steroids, and adrenal replacement steroid > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease. Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is permitted. Patients requiring steroids as a once-off, short term anti-emetics (such as that prescribed with chemotherapy) are eligible. 14) Interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity. 15) Has a history of non-infectious pneumonitis requiring treatment with steroids. 16) Known medical condition that, in the investigator’s opinion, would increase the risk associated with study participation or study drug administration or interfere with the interpretation of safety results. 17) Treatment with botanical preparations (e.g. herbal supplements) and traditional Chinese medicines, intended for general health support or to treat the disease under study, within 7 days before randomisation/registration. 18) Participants considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent. 19) Pregnant; lactating participants must stop breast feeding before randomisation/registration. Use of oral, injectable or implant hormonal contraceptives or medicated IUD must stop before randomisation/registration. 20) Contraindications or known hypersensitivity to the study medication or excipients. 21) Administration of a live vaccine within 30 days before randomisation/registration. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed, however intranasal influenza vaccines (e.g. FluMist®) are live attenuated vaccines and are not allowed. 22) Known history of testing positive for Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies) or known acquired immunodeficiency syndrome (AIDS). 23) Positive test result for HbsAg (hepatitis B surface antigen) unless HBV (hepatitis B virus) deoxyribonucleic acid (DNA) < 500 IU/mL and participant is on antiviral therapy. 24) Positive test result for hepatitis C virus (HCV) antibody unless HCV-ribonucleic acid (RNA) is undetectable. 25) Participants on antiviral therapy for HCV (participants who have completed antiviral therapy for HCV and who have undetectable levels of HCV-RNA are allowed). 26) Active co-infection (Hep B and Hep C) OR (Hep B and Hep D). 27) Active tuberculosis infection (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice).
Outcome results
None listed